• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Premier Biomedical Provides Update Letter from CEO

    Bryan Mc Govern
    Jul. 17, 2017 08:43AM PST
    Biotech Investing

    Premier Biomedical shared the publication of an update letter to shareholders from the company’s CEO.

    Premier Biomedical (OTCQB:BIEI) shared the publication of an update letter to shareholders from the company’s CEO William Hartman.
    As quoted in the press release:

    Summary.

    • This first half, we cleared our books of convertible debt, launched a revenue-generating product line, and secured more conventional financing with incentives for the lender to appreciate, rather than depreciate our stock price.
    • We established a number of direct distributors, including pharmacies and health clinics.
    • Now that we have resolved the product formulations and volume manufacturing to our specifications, we are attempting to expand our distributor networks both within North America as well as off-shore.
    • We are in the process of developing, and launching several additional pain relieving products which we intend to spot-market test.

    We have been very busy building our business, and now that we have resolved the basic issue of developing an industry-best formulation and a volume manufacturing system, we are poised to expand our business geometrically. We thank our loyal stockholders and pledge that we will continue our efforts on their behalf. We thank you for your continued support.

    Click here to read the full press release.

    Source: www.marketwired.com

    The Conversation (0)

    Go Deeper

    AI Powered
    Life Science Outlook

    Life Science Outlook

    BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

    BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
      • Electric Vehicles
    • Agriculture
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Energy
      • Uranium
      • Oil and Gas
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Robotics
      • Crypto
      • Cleantech
    Life Science
      • Biotech
      • Cannabis
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES